Anti-Cyclic Citrullinated Peptide IgA (Anti-CCP IgA)
Anti-CCP IgA is an antibody that targets citrullinated proteins and is used to diagnose rheumatoid arthritis and other inflammatory conditions.
Anti-CCP IgA is a diagnostic biomarker for rheumatoid arthritis and inflammatory diseases.
Key facts at a glance
- Units
- U/mL
- Clinical utility
- diagnostic
- Result kind
- quantitative
- FDA-cleared
- Roche Anti-CCP IgA
Anti-Cyclic Citrullinated Peptide IgA (Anti-CCP IgA) is an antibody that binds to citrullinated proteins, which are proteins that have undergone a post-translational modification. This biomarker is primarily associated with rheumatoid arthritis (RA) and other inflammatory conditions.
The presence of Anti-CCP IgA antibodies in the blood can indicate the development of RA even before clinical symptoms appear. This makes it a valuable tool for early diagnosis and intervention.
Measuring Anti-CCP IgA levels can help differentiate RA from other types of arthritis and guide treatment strategies. Elevated levels are typically indicative of a more severe disease course.
Frequently asked questions
What is the normal range for Anti-CCP IgA?
What does a high Anti-CCP IgA level indicate?
Sources
- 1
- 2
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy